McKinsey’s Hidden Influence
Motley Fool Money
00:00
McKinsey's Ethical Quandaries
This chapter examines McKinsey's contentious ties with pharmaceutical companies and its influence on FDA drug approvals, focusing on the case of Biogen's controversial Alzheimer's drug, Adahelm. It further explores McKinsey's ongoing collaboration with the tobacco industry and its secretive operations, raising questions about ethical practices in consulting. Additionally, the chapter reflects on McKinsey's work with Chinese state-owned enterprises amid rising geopolitical tensions, highlighting the complexities of their global consulting strategies.
Transcript
Play full episode
